We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 31

EU Court of Justice Advocate General issues ruling on Stem Cell patentability
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom
  • August 7 2014

In a non-binding ruling, Advocate General Cruz Villalón of the EU Court of Justice has determined that unfertilized human ova whose division


EU agency will reinstate Ranbaxy’s GMP certificate
  • Shook Hardy & Bacon LLP
  • European Union, India
  • June 12 2014

The European Medicines Agency (EMA) has reportedly concluded its investigation of alleged non-compliance with good manufacturing practice (GMP) at


Wellcome Trust creates £200-million fund for UK, EU biotech startups
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom
  • March 29 2012

The U.K.-based Wellcome Trust has announced the creation of a £200-million fund to make long-term investments in British and European biotechnology startups


Public-private EU partnership to fund stem cell banking and distribution
  • Shook Hardy & Bacon LLP
  • European Union
  • February 13 2014

A consortium of public and private partners has reportedly formed to establish a European induced pluripotent stem (iPS) cell bank with the goal of


Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom, USA, Australia, Canada
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies


EU Medicines Agency plans to appeal interim rulings on release of clinical trial data
  • Shook Hardy & Bacon LLP
  • European Union
  • May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European


April vote scheduled before EU Parliament on clinical trial data accessibility
  • Shook Hardy & Bacon LLP
  • European Union
  • March 20 2014

The European Parliament has postponed until April 2, 2014, debate on amended draft legislation (20120192 (COD)) that would require phar- maceutical


EU adds pharmaceuticals to water pollution watch list
  • Shook Hardy & Bacon LLP
  • European Union
  • July 11 2013

The European Commission (EC) has added 12 new substances to the European Union's (EU's) priority list of chemicals known to pose a risk to the safety


European Medicines Agency considers changes to biosimilar guidelines
  • Shook Hardy & Bacon LLP
  • European Union
  • October 20 2011

The European Medicines Agency (EMA) has published a concept paper outlining a number of clinical and non-clinical issues that need revision in its current “Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance"


EU adopts joint procurement agreement for pandemic vaccines
  • Shook Hardy & Bacon LLP
  • European Union
  • April 17 2014

The European Commission has approved a joint procurement agreement under which all European Union (EU) member states will be able to "procure